Rubrique en cours de formatage. Si vous souhaitez nous aider à la mettre en forme (ajout saut de ligne, gras, etc…) n’hésitez pas à nous contacter sur edito [at] ufcmed.org

Cette page  répertorie plus de 300 références scientifiques utilisées dans les articles de UFCMed et le livre Cannabis en Médecine. Les références incluent des publications de la presse spécialisée relatives aux études cliniques, aux recherches et aux rapports d’études de cas sur les traitements à base de cannabinoïdes et de cannabis.

Littérature spécifique (en anglais)
British Medical Association: Therapeutic uses of cannabis. Harwood Academic Publishers, Amsterdam 1997.
Cannabis. The scientific and medical evidence. Select Committee on Science and Technology. House of Lords, 9th Report session, 1997-98. London: The Stationery Office, 1998.
Grotenhermen F, Russo E, eds. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Bing-hamton/New York: Haworth Press, 2002.
Joy JE, Watson SJ, Benson JA, eds. Marijuana and medicine: Assessing the science base. Washington DC: Institute of Medicine, National Academy Press, 1999.
Russo E, Grotenhermen F, Hrsg. The Handbook of Cannabis Therapeutics: From Bench to Bedside. Binghamton/New York: Haworth Press, 2006.
Une partie de la littérature spécifique est disponible sur le site internet de l’IACM.
Nausées et vomissements
Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 1995;56:2097-2102.
Artim R, DiBella N. Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V). Proceedings of the American Society for Clinical Oncology 1983;2:84.
Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I. Delta-9-tetrahydrocannabinol as an antiemetics in
182
cancer patients receiving high-dose methotrexate. Annals of Internal Medicine 1979;91:819-824.
Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Rosenberg SA.. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746-1751.
Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. New Zealand Medical Journal 1980;91:449-451.
Costiniuk CT, Mills E, Cooper CL. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008;22(4):376-80.
De Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr 2005;38(1):43-6.
Doblin RE, Kleiman MA. Marijuana as antiemetic medicine: a survey of oncologists’ experiences and attitudes. American Journal of Clinical Oncology 1991; 9: 1314-1319
Ekert H, Waters KD, Jurk KH, Mobilia J, Loughnan P. Ameriloration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2:657-659.
Frytak S, Moertel CG, O’Fallon JR, Rubin J, Creagan ET, O’Connnell MJ. Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Annals of Internal Medicine 1979;91:825-830.
Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (Dronabinol). Journal of Pain and Symptom Management 1997;14(5):311-314.
Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treatment Report 1984;68:163-172.
Kluin-Nelemans JC, Nelemans FA, Meuwissen OJATh, Maes RAA. 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated
183
with cancer chemotherapy; a double-blind cross-over trial against placebo. Veterinary and Human Toxicology 1979;21:338-340.
Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management 1991;6:352-359.
Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, Klimberg VS. Prevention of nausea and vomiting following breast surgery. Am J Surg 2006;191(6):767-72.
Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics. Proceedings of the American Society for Clinical Oncology 1984;3:91.
Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics. Proceedings of the American Society for Clinical Oncology 1984;3:91.
Levitt M, Wilson A, Bowman D, Faiman C, Kemel S, Krepart G. Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics. Proceedings of the American Society for Clinical Oncology 1981;22:422.
McCabe M, Smith FP, Goldberg D, Macdonald J, Woolley PV, Warren R. Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy. Investigational New Drugs 1988;6:243-246.
Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007;23(3):533-43.
Merriman AR, Oliak DA. Use of medical marijuana for treatment of severe intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery: case report. Surg Obes Relat Dis, 26 January 2008.
Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. International Journal of Clinical Pharmacology Research 1981; 21: 38-42S
Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Archives of Internal Medicine 1980;140:1431-433.
Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of
184
delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of Medicine 1980;302:135-138.
Sallan SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England Journal of Medicine 1975;293:795-797.
Schwartz RH, Voth EA, Sheridan MJ. Marijuana to prevent nausea and vomiting in cancer patients: a survey of clinical oncologists. Schwartz RH, Voth EA, Sheridan MJ.
Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacology, Biochemistry and Behavior 2001;69(3-4):343-50.
Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 2006;18(10):1057-63.
Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 1982;50:636-645.
Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer chemotherapy patientthe UCLA study. Part II: patient drug preference. American Journal of Clinical Oncology 1985; 8: 142-147.
Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State Journal of Medicine 1988;88:525-527.
Westfall RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’. Complement Ther Clin Pract 2006;12(1):27-33.
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.
Zutt M, Hanssle H, Emmert S, Neumann C, Kretschmer L. [Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases] [Article in German]. Hautarzt 2006;57(5):423-7.
Cancer
Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with
185
recurrent glioblastoma multiforme. Br J Cancer 2006;95(2):197-203.
Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, Mack TM, Greenland S. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1829-34.
Spasticité
Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. International Journal of Clinical Pharmacology and Therapeutics 1996;34:446-452.
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 2006;12(5):646-51.
Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. 22nd Congress of the ECTRIMS, 27-30 September 2006, Madrid, Spain.
Collin C, Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurology 2007;14(3):290–296.
Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology 1997;38:44-48.
Consroe P, Tillery W, Rein J, Musty RE. Reported Marijuana effects in patients with spinal cord injury. 1998 Symposium on the Cannabinoids. Burlington: International Cannabinoid Research Society, 1998, p. 64.
Deutsch SI, Rosse RB, Connor JM, Burket JA, Murphy ME, Fox FJ. Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. CNS Spectr 2008;13(5):393-403.
Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974;12:175.
Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clinical Pharmacology and Therapeutics 1994;55:324-328.
186
Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with 9-tetrahydrocannabinol (9-THC) in patients with spinal cord injury. IACM 2nd Conference on Cannabinoids in Medicine, Cologne, 12-13 September 2003, International Association for Cannabis as Medicine.
Hagenbach U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R, Mäder M. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45(8):551-62.
Hanigan WC, Destree R, Truong XT. The effect of 9-THC on human spasticity. Clinical Pharmacology and Therapeutics 1986;39:198.
Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58(9):1404-7.
Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA. Treatment of spasticity in spinal cord injury with Dronabinol, a tetrahydrocannabinol derivative. American Journal of Therapeutics 1995;2(10):799-805.
Malec J, Harvey RF, Cayner JJ. Cannabis effect on spasticity in spinal cord injury. Archives of Physical Medicine and Rehabilitation 1982;63:116-118.
Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579.
Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. European Archives of Psychiatry and Clinical Neuroscience 1990;240:1-4.
Meinck HM, Schönle PWA, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. Journal of Neurology 1989;236:120-122.
Petro DJ, Ellenberger C. Treatment of human spasticity with 9-tetrahydrocannabinol. Journal of Clinical Pharmacology 1981;(Suppl 21):413S-416S.
Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.
Randall RC, ed. Muscle Spasm, Pain & Marijuana Therapy. Washington, DC: Galen Press, 1991.
Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. 9-THC in the treatment of spasticity associated with multiple sclerosis. Advances in Alcohol and Substance Abuse 1987;7:39-50.
187
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Multiple Sclerosis 2004;10(4):417-24.
Vaney C. A clinical study with a standardized cannabis extract in multiple sclerosis. Paper presented at 2001 Conference of the International Association for Cannabis as Medicine in Berlin, October 26-27, 2001.
Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 2004;10(4):434-41.
Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45.
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilition 2003;17:18-26.
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1664-9.
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1664-9.
Voies urinaires excrétrices
Brady CM, DasGupta R, Wiseman OJ, Berkley KJ, Fowler CJ. Acute and chronic effects of cannabis based medicinal extract on refractory lower urinary tract dysfunction in patients with advanced multiple sclerosis – early results. 2001 Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Association for Cannabis as Medicine, p. 9.
188
Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 2004;10(4):425-33.
De Ridder D, Constantinescu CS,Fowler C, Kavia R, Sarantis N. Randomised controlled study of cannabis-based medicine (Sativex®) in patients suffering from multiple sclerosis associated detrusor overactivity. 22nd Congress of the ECTRIMS, 27-30 September 2006, Madrid, Spain.
Hagenbach U, Ghafoor N, Brenneisen R, Luz S, Mäder M. Clinical investigation of -9-tetrahydrocannabinol (THC) as an alternative therapy for overactive bladders in spinal cord injury (SCI) patients? 2001 Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Association for Cannabis as Medicine, p. 10.
Tremblements
Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology 1983;13:669-671.
Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62(7):1105-9.
Dystonie
Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience 1986;30:277-282.
Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders 2002;17(1):145-149.
Sandyk R, Snider SR, Consroe P, Elias SM. Cannabidiol in dystonic movement disorders. Psychiatry Research 1986;18:291.
Snider SR, Consroe P. Treatment of Meige’s syndrome with cannabidiol. Neurology 1984;34(Suppl):147.
Syndrome de Gilles de la Tourette
Deutsch SI, Rosse RB, Connor JM, Burket JA, Murphy ME, Fox FJ. Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. CNS Spectr 2008;13(5):393-403.
189
Hemming M, Yellowlees PM. Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 1993; 7: 389-91.
Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiatrica Scandinavica 1998;97:1-5.
Müller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61.
Müller-Vahl KR, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol. American Journal of Psychiatry 1999;156:495.
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. Journal of Clinical Psychiatry. 2003;64(4):459-65.
Sandyk R, Awerbuch G. Marijuana and Tourette’s Syndrome. Journal of Clinical Psychopharmacology 1988;8:444-445.
Maladie de Parkinson
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63(7):1245-50.
Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for Parkinsonian tremor. Journal of Neurology, Neurosurgery and Psychiatry 1990;53:436.
Dyskinésie induite par lévodopa / hyperkinésie
Farooq MU, Ducommun E, Goudreau J. Treatment of a hyperkinetic movement disorder during pregnancy with dronabinol. Parkinsonism Relat Disord. 2009 Mar;15(3):249-51.
Sieradzan KA, Fox SH, Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD). Movement Disorders 1998;13(Suppl 2):29.
Snider SR, Consroe P. Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia. Neurology 1985;35(Suppl):201.
190
Chorée de Huntington
Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled clincal trial of cannabidiol in Huntington’s disease. Pharmacology, Biochemistry and Behavior. 1991;40(3):701-8.
Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington’s disease. J Neuropsychiatry Clin Neurosci 2006;18(4):553-4.
Müller-Vahl KR, Schneider U, Emrich HM. Nabilone deteriorates choreatic movements in Huntington`s disease. Movement Disorders 1999;14:1038-40.
Douleurs physiques
Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007;68(7):515-21.
Abrams DI, Jay Ch, Petersen K, Shade S, Vizoso H, Reda H, Benowitz N, Rowbotham M. The effects of smoked cannabis in painful peripheral neuropathy and cancer pain refractory to opiods. IACM 2nd Conference on Cannabinoids in Medicine, Cologne, 12-13 September 2003, International Association for Cannabis as Medicine.
Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004;8:173–177.
Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006;53(8):769-75.
Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112(3):299-306.
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45(1):50-2.
Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. International Journal of Clinical Pharmacology and Therapeutics 1996;34:446-452.
Butler JR Peek LA Regelson W Moore MM Lubin LA. Treatment effects of delta-9-THC in an advanced cancer population. In:
191
Cohen S, Stillman RC, eds. The therapeutic potential of marihuana. Plenum Medical Book, New York 1976.
Chatterjee A, Almahrezi A, Ware M, Fitzcharles MA. A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. J Pain Symptom Manage 2002 Jul;24(1):4-6.
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 2006;12(5):646-51.
Clermont-Gnamien S, Atlani S, Attal N, Le Mercier F, Guirimand F, Brasseur L. [The therapeutic use of D9-tetrahydrocannabinol (Dronabinol) in refractory neuropathic pain] [Article in French]. Presse Med 2002;31(39 Pt 1):1840-5.
Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology 1997;38:44-48.
Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974;12:175.
Elsner F, Radbruch L, Sabatowski R. Tetrahydrocannabinol zur Therapie chronischer Schmerzen Tetrahydrocannabinol for treatment of chronic pain. Schmerz 2001;15(3):200-4.
Ernst G, Denke C, Reif M, Schnelle M, Hagmeister H. Standardized cannabis extract in the treatment of postherpetic neuralgia: a randomized, double-blind, placebo-controlled cross-over study. IACM 3rd Conference on Cannabinoids in Medicine, 9-10 September 2005, Leiden, International Association for Cannabis as Medicine.
Finnegan-Ling D, Musty RE. Marinol and phantom limb pain; a case study. In: 1994 Symposium on the Cannabinoids. Burlington, Vermont: International Cannabinoid Research Society, p. 53.
Fiz J, Duran M, Langohr K, Capellà D, Farré M. Symptoms relief and improved mental health in fibromyalgia patients using cannabis. Results of an observational study. IACM 4th Conference on Cannabinoids in Medicine, 5-6 October 2007, Cologne, International Association for Cannabis as Medicine.
Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336(7637):199-201.
Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006;104(5):1040-1046.
192
Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-488.
Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a questionnaire study. Br J Haematol 2005;131(1):123-8.
Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. Journal of Clinical Pharmacology 1981;21(suppl 8-9):S320-S326.
Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr R. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology and Therapeutics 1978;24:223-7.
Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. British Pain Society; 2005 March 8-11; Edinburgh, Scotland.
Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. British Pain Society; 2005 March 8-11; Edinburgh, Scotland.
Kantor TG, Hopper M. A study of levonantradol, a cannabinol derivative, for analgesia in post operative pain. Pain 1981; (suppl): S37.
Lindstrom P, Lindblom U, Boreus L. Lack of effect of cannabidiol in sustained neuropathia. Paper presented at ’87 International Conference on Cannabis, Melbourne, September 2-4, 1987. Cited from: Consroe P, Sandyk R. Potential role of cannabinoids for therapy of neurological disorders. In: Murphy L, Bartke A, eds. Marijuana/Cannabinoids. Neurobiology and Neurophysiology. Boca Raton, CRC Press, 1992:459-524.
Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage 2003;25(6):496-8.
Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 2008;6(3):119-24.
193
Maida V. The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients. Abstract of San Antonio Breast Cancer Symposium, 15 December 2006.
Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-THC shows antispastic and analgesic effects in a single case double blind trial. European Archives of Psychiatry and Clinical Neuroscience 1990;240:1-4.
Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008;9(3):254-64.
Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 2004;59(5):440-52.
Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 2004;59(5):440-52.
Noyes R, Baram DA. Cannabis analgesia. Comprehensive Psychiatry 1974:15:531-535.
Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effects of delta-9-THC. Journal of Clinical Pharmacology 1975;15:139-143.
Noyes R, Brunk ST, Avery DH, Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology and Therapeutics 1975;18:84-89.
Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3):210-20.
Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.
Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain – a randomized controlled trial.] [Artikel in deutsch] Wien Klin Wochenschr 2006;118(11-12):327-35.
Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
194
Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clinical Pharmacology and Therapeutics 1977;21:26-33.
Redmond WJ, Goffaux P, Potvin S, Marchand S. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin 2008;24(4):1017-24.
Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006;530(1-2):54-8.
Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9.
Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29(9):2068-79.
Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006;22(7):1269-1276.
Seeling W, Kneer L, Buchele B, Gschwend JE, Maier L, Nett C, Simmet T, Steffen P, Schneider M, Rockemann M. [(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [Article in German]. Anaesthesist 2006;55(4):391-400.
Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-73.
Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology and Therapeutics 1978;23:397-401.
Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329(7460):253.
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 2003;17:18-26.
Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107(5):785-796.
195
Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003;102(1-2):211-6.
Ware MA, Ducruet T, Robinson AR. Evaluation of herbal cannabis characteristics by medical users: a randomized trial. Harm Reduct J 2006;3(1):32
Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9(6):506-21.
Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol 2006;253(10):1337-41.
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.
Perte de l’appétit et amaigrissement
Beal JE, Olson R, Laubenstein L, Morales JP, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management 1995;10(2):89-97.
Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV. Long-term efficacy and safety of Dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management 1997;14(1):7-14.
Bergmann K-C. [Dronabinol, a possible new therapeutic option in patients with COPD and pulmonal cachexia] [Article in German]. Abstract, 2005 Conference of the German Society for Pneumology, 17 March 2005, Berlin.
Dejesus E, Rodwick BM, Bowers D, Cohen CJ, Pearce D. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc Physicians AIDS Care 2007;6(2):95-100.
Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988;11(1):1-14.
Foltin RW, Fishman MW, Brady JV. Behavioral analysis of marijuana effects on food intake in humans. Pharmacology, Biochemistry and Behavior 1986;25:577-582.
196
Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS 1992;6:127.
Gross H, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, Hawks R, Zinberg N. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology 1983;3(3):165-171.
Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007;45(5):545-54.
Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007;45(5):545-54.
Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 2005;181(1):170-8.
Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 2005;181(1):170-8.
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology 2002;20(2):567-573.
Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Journal of Palliative Care 1994;10:14-18.
Plasse T, Conant M, Gorter R, Shepard KV. Dronabinol stimulates appetite and causes weight gain in HIV patients. International Conference on AIDS 1992;8(3):122.
Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with Dronabinol. Pharmacology, Biochemistry and Behavior 1991;40:695-700.
Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with Dronabinol. Pharmacology, Biochemistry and Behavior 1991;40:695-700.
Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
197
Regelson W, Butler JR, Schulz J, Kirk T, Peek L, Green ML, Zalis MO. Tetrahydrocannbinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S, eds. The pharmacology of marihuana. Raven Press: New York: 1976;763-776.
Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol 2006;24(21):3394-400.
Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol 2006;24(21):3394-400.
Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG. Effect of Dronabinol on nutritional status in HIV infection. Annals of Pharmacotherapy 1993;27:827-831.
Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G, and the DATRI 004 Study Group. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and Dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses 1997;13:305-315.
Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry 1997;12:913-919.
Wadleigh R, Spaulding GM, Lumbersky B, Zimmer M, Shepard K, Plasse T. Dronabinol enhancement of appetite in cancer patients. Proc Am Soc Oncology 1990; 9: 331.
Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant? – a pilot study. J Nutr Health Aging 2007;11(2):195-8.
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.
198
Épilepsie
Ames FR, Cridland S. Anticonvulsant effect of cannabidiol [letter]. South African Medical Journal 1986;69:14.
Consroe PF, Wood GC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975;234(3):306-7.
Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-85.
Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Conference on Cannabis and Cannabinoids, Kolympari/Crete, July 1990, cited according to: Consroe P, Sandyk R. Potential role of cannabinoids for therapy of neurological disorders. In: Murphy L, Bartke A, eds. Marijuana/Cannabinoids, Neurobiology and Neurophysiology. Boca Raton: CRC Press 1992, 459-524.
Glaucome et trouble de la pression intraoculaire
Cooler P, Gregg JM. Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans. Southern Medical Journal 1977;70(8):951-954.
Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. International Journal of Clinical Pharmacololgy and Biopharmacy 1979;17(5):191-196.
Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced intraocular pressure in human eye: Drug action or epiphenomenon? Investigative Ophthalmology 1975;14:52-55.
Hepler R S, Frank I M, Petrus R. Ocular effects of marijuana smoking. In: Braude MC, Szara S, eds. The pharmacology of marihuana. New York: Raven Press, 1976;815-828.
Hepler RS, Frank IM. Marihuana smoking and intraocular pressure. Journal of the American Medical Association 1971;217:1392.
Jones RT, Benowitz N, Herning RI. The clinical relevance of cannabis tolerance and dependence. Journal of Clinical Pharmacology 1981;21:143S-152S.
Levitt M, Wilson A, Bowman D, Kemel S, Krepart G, Marks V, Schipper H, Thomson G, Weinerman B, Weinerman R. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 1981;21(8-9 Suppl):103S-109S.
199
Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980;87(3):222-8.
Merritt JC, Perry DD, Russell DN, Jones BF. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Journal of Clinical Pharmacololgy 1981;21(8-9 Suppl):467S-471S.
Perez-Reyes M, Wagner D, Wall ME. Davis KH. Intravenous administration of cannabinoids and intraocular pressure. In: Braude MC, Szara S, ed. Pharmacology of marihuana. New York: Raven Press, 1976;829-832.
Plange N, Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel WE, Remky A. Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 2007;143(1):173-4.
Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 2006;15(5):349-353.

Asthme et troubles respiratoires
Gong H Jr, Tashkin DP, Calvarese B. Comparison of bronchial effects of nabilone and terbutaline in healthy and asthmatic subjects. Journal of Clinical Pharmacology 1983;23(4):127-133
Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clinical Pharmacology and Therapeutics 1984;35(1):26-32.
Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects. American Review of Respiratory Disease 1977;115(1):57-65.
Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. American Review for Respiratory Diseases. 1974 Apr;109(4):420-8.
Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Effects of smoked marijuana in experimentally induced asthma. American Review of Respiratory Disease 1975;112(3):377-386.
Vachon L, Mikus P, Morrissey W, FitzGerald M, Gaensler E. Bronchial effect of marihuana smoke in asthma. In: Braude MC, Szara S, eds. The pharmacology of marihuana. Raven Press: New York: 1976;777-784.
Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1976;31(6):720-723.
200
Maladies psychiatriques
Mikuriya TH. Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism. Medical Times 1970;98(4):187-91.
Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of Dronabinol on anorexia and disturbed behavior in patients with
Maladie d’Alzheimer
Alzheimer’s disease. International Journal of Geriatric Psychiatry 1997;12:913-919.
Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006;185(4):524-8.
Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. Journal of Clinical Psychiatry 1995;56:485-486.
Schizophrénie
Leweke FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Hänsel A, Neatby MA, Juelicher A, Hellmich M, Klosterkötter J. Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on cannabidiol vs. amisulpride in acute schizophrenia. IACM 3rd Conference on Cannabinoids in Medicine, 9-10 September 2005, Leiden, International Association for Cannabis as Medicine.
Schwarcz G, Karajgi B, McCarthy R. Synthetic delta-9- tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol 2009;29(3):255-8.
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, Musty RE, Crippa JA. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20(5):683-6.
Trouble bipolaire
El-Mallakh RS, Brown C. The effect of extreme marijuana use on the long-term course of bipolar I illness: a single case study. J Psychoactive Drugs 2007;39(2):201-2.
Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. Journal of Psychoactive Drugs 1998;30(2):171-7.
Van Rossum I, Boomsma M, Tenback D, Reed C, van Os J; EMBLEM Advisory Board. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis 2009;197(1):35-40.
201
Dépression
Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005;59(3):291-5.
Trouble obsessionnel compulsif (TOC)
Schindler F, Anghelescu I, Regen F, Jockers-Scherubl M. Improvement in refractory obsessive compulsive disorder with dronabinol. Am J Psychiatry 2008;165(4):536-7.
Trouble Déficit de l’Attention Hyperactivité (TDAH)
Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. Am J Drug Alcohol Abuse. 2006;32(4):629-35.
O’Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007;4:16.
Strohbeck-Kuehner P, Skopp G, Mattern R. [Fitness to drive in spite (because) of THC] [Article in German]. Arch Kriminol 2007;220(1-2):11-9.
Maux de tête, migraines
Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis 2007;4(2):103-6.
Raby WN, Modica PA, Wolintz RJ, Murtaugh K. Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
Côlon irritable, diarrhées
Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol.
Dépendances aux drogues – addictions
Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome.
202
Am J Drug Alcohol Abuse. 2006;32(4):629-35.
Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004;29(1):158-70.
Hermann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Addict Biol 2005;10(2):165-9.
Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict 2008;17(2):161-4.
O’Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007;4:16.
Troubles du sommeil et insomnies
Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 2004;24(3):305-13.
Autres maladies
Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21(2):95-104.
Grotenhermen F, Schnelle M. Survey on the medical use of cannabis and THC in Germany. Journal of Cannabis Therapeutics 2003;3(2):17-40.
Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42(1):63-71.
Ho WS, Gardiner SM. Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol. 2009 Jan;156(1):94-104.
Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008;6(1):69-75.
Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tüting T, Zimmer A. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007 Jun 8;316(5830):1494-7.
203
Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N; Pharmos TBI investigators. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006;5(1):38-45.
Raby WN, Modica PA, Wolintz RJ, Murtaugh K. Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
Schnelle M, Grotenhermen F, Reif M, Gorter RW. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von Cannabisprodukten im deutschen Sprachraum, [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. Forschende Komplementärmedizin, [Research in Complementary Medicine] 1999;(Suppl 3) 28-36.
Ständer S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists: An effective new possibility for treating chronic pruritus.] [Article in German]. Hautarzt 2006;57(9):801-7.
Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C._EUR J Gastroenterol Hepatol 2006;18(10):1057- 63.
Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005;13(2):97-103.
Zheng Y, Baek JH, Smith PF, Darlington CL. Cannabinoid receptor down-regulation in the ventral cochlear nucleus in a salicylate model of tinnitus. Hear Res. 2007 Jun;228(1-2):105-11.
Articles sélectionnés traitant de la recherche fondamentale, commentaires et synthèses
Abel EL. Marihuana and sex. A critical survey. Drug and Alcohol Dependence 1981;8:1–22.
Allentuck, S. Medical aspects. In: Cattell, J ed. The Marijuana Problem in the City of new York. Ronald Press, New York 1944, 35-64. Reprint in: Mikuriya, TH (ed.): Marjuana: Medical Papers 1839-1972. Medi-Comp Press, Oakland 1973.
Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. Journal of Neuroscience 2003;23(7):2511-6.
Babor TF, Mendelson JH, Kuehnle J. Marihuana and human physical activity. Psychopharmacology (Berl) 1976;50(1):11-9
204
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffmann JW, Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-87.
Barsch G. Zur therapeutischen Anwendung von Cannabis: Ergebnisse einer Pilotstudie unter HIV-positiven und Aids-kranken Männern und Frauen. In: Deutsche Aids Hilfe, ed. Cannabis als Medizin. Beiträge auf einer Fachtagung zu einem drängenden Thema. Berlin: Aids-Forum D.A.H, 1996.
Berkley KJ, Dmitrieva N. Influence of synthetic cannabinoid ligands on the rat bladder and uterus: clinical implications. 2001 Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Asociation for Cannabis as Medicine, p. 9.
Burstein S. Das therapeutische Potenzial der ajulämischen Säure (CT3). In: Grotenhermen F. (Hrsg.). Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potenzial. Bern: Huber, 2001.
Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2; 408(6808): 96-101.
Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2; 408(6808): 96-101
Carley DW, Paviovic S, Janelidze M, Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002; 25(4): 391-8.
Carter GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001;18(4):264-70.
Cohen S. Cannabis and sex: Multifaceted paradoxes. Journal of Psychoactive Drugs 1982;14:55-58.
Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. Journal of Clinical Investigation 2003;111(8):1231-40.
Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacology, Biochemistry and Behavior 2001; 69(1-2): 239-49.
Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410(6830): 822-5.
205
Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410(6830):822-5.
Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis Sativa L. on human and rabbit platelet aggregation. Journal of Pharmacy and Pharmacology 1989; 41(10): 705-9.
Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of cannabis Sativa l. on human and rabbit platelet aggregation. Journal of Pharmacy and Pharmacology 1989;41:705-09.
Fronmüller B. Klinische Studien über die schlafmachende Wirkung der narkotischen Arzneimittel. Erlangen 1869.
Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 2000;6(3):313-9.
Gieringer D. Medizinische Verwendung von Marihuana: Erfahrungen aus Kalifornien. In: Grotenhermen F. (Hrsg.). Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potenzial. Huber, Bern 2001.
Gilson I, Busalacchi M. Marijuana for intractable hiccups. Lancet 1998; 351(9098): 267.
Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001;42(10):1266-72.
Greenberg, I, Kuehnle, J, Mendelson, JH, Bernstein, JG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology 1976; 49,79-84.
Grinspoon L, Bakalar JB. Marihuana – Die verbotene Medizin. Frankfurt am Main: Zweitausendeins, 1994.
Hampson A. Cannabinoide als Neuroprotektiva gegen Ischämie. In: Grotenhermen F. (Hrsg.). Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potenzial. Bern: Huber, 2001.
Hare HA. Practical Therapeutics. Philadelphia: Blakiston 1922.
Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, Capasso F. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. British Journal of Pharmacology 2001;134(3):563-70.
206
Jan TR, Farraj AK, Harkema JR, Kaminski NE. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol Appl Pharmacol 2003;188(1):24-35.
Koff WC. Marijuana and sexual activity. Journal of Sex Research 1974;10:194-204.
Krystal JH, D’Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999;35 Suppl:S35-49.
Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 1989;23(1):73-81.
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418(6897):530-4
Mechoulam R, Shohami E, Fride E, Bab I. The ubiquitous role of endocannabinoids in physiological processes: examples in neuroprotection, feeding and bone formation. First European Workshop on Cannabinoid Research. Madrid (Spain), 2003.
Mechoulam R, Shohami E. HU-211, ein neuroprotektives Cannabinoid. In: Grotenhermen F. (Hrsg.). Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potenzial. Bern: Huber, 2001.
Melamede R. Mögliche Mechanismen bei Autoimmunerkrankungen. In: Grotenhermen F. (Hrsg.). Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potenzial. Bern: Huber, 2001.
Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141(1):118-26.
Milton NG. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 2002;332(2):127-30
Musty RE, Rossi I. Effects of smoked cannabis and oral 9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. Journal of Cannabis Therapeutics 2001;1(1):29-42.
207
Neff GW, O’Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with Dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. American Journal of Gastroenterology 2002;97(8):2117-9.
O’Shaugnessy WB. On the preparations of the Indian hemp, or Gunjah, Transactions of the Medical and Physical Society of Bengal (1838-40), 421-461. Reprint in: Mikuriya TH, ed. Marijuana: Medical papers 1839-1972. Oakland: Medi-Comp Press, 1973.
Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002;13(5):567-70.
Pate D. Glaukom. In: Grotenhermen F. (Hrsg.). Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potenzial. Bern: Huber, 2001.
Richter A, Löscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. European Journal of Pharmacology 1994;264:371-377
Russo E, Merzouki A, Mesa JM, Frey K. Cannabis improves night vision: a pilot study of visual threshold and dark adaptometry in kif smokers in the rif region of northern Morocco. 2003 Congress on Cannabinoids in Medicine, Cologne, Germany: International Association for Cannabis as Medicine.
Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM, Kennard C. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999;53(9):2209-10.
See G. Anwendung der Cannabis Indica in der Behandlung der Neurosen und gastrischen Dyspepsieen. Deutsche Medizinische Wochenschrift 1890;60(31-34):679-682, 727-730, 748-754, 771-774.
Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249(2): 444-9.
Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. European Journal of Pharmacology 2001; 415(1): R5-R7.
Sofia RD, Nalepa SD, Harakal JJ, Vassar HB. Anti-edema and analgesic properties of 9-tetrahydrocannabinol (9-THC). Journal
208
of Pharmacology and Experimental Therapeutics 1973;186:646-655.
Sofia, RD, Diamantis, W, Harrison, JE, Melton J. Evaluation of antiulcer activity of delta9-tetrahydrocannabinol in the Shay rat test. Pharmacology 1987;17:173-177.
Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323(7303):16-21.
Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. International Journal of Clinical Pharmacology Research 1985;5(4):243-246.
Wagner JA, Hu K, Karcher J, Bauersachs J, Schafer A, Laser M, Han H, Ertl G. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. British Journal of Pharmacology 2003;138(7):1251-8.
Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. European Journal of Pharmacology 2002;452(3):295-301.
Walton RP. Description of the hashish experience. In: Marihuana: America`s New Drug Problem. Philadelphia: JB Lippincott, 1938.
Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994;28(3):209-214.
Chènevis, huile et farine de chanvre
Andreassi M, Forleo P, Di Lorio A, Masci S, Abate G, Amerio P. Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res 1997;25(5):266-74.
Anstey A, Quigley M, Wilkinson JD. Tropical evening primrose oil as treatment for atopic eczema. J Dermatol Treat 1990;1:199-201.
Biagi PL, Bordoni A, Hrelia S, Celadon M, Ricci GP, Cannella V, Patrizi A, Specchia F, Masi M. The effect of gamma-linolenic acid on clinical status, red cell fatty acid composition and membrane microviscosity in infants with atopic dermatitis. Drugs Exp Clin Res 1994;20(2):77-84.
209
Biagi PL, Bordoni A, Masi M, Ricci G, Fanelli C, Patrizi A, Ceccolini E. A long-term study on the use of evening primrose oil (Efamol) in atopic children. Drugs Exp Clin Res 1988;14(4):285-90.
Bordoni A, Biagi PL, Masi M, Ricci G, Fanelli C, Patrizi A, Ceccolini E. Evening primrose oil (Efamol) in the treatment of children with atopic eczema. Drugs Exp Clin Res 1988;14(4):291-7.
Borrek S, Hildebrandt A, Forster J. Gammalinolensaure-reiche Borretschsamenol-Kapseln bei Kindern mit Atopischer Dermatitis. Eine placebo-kontrollierte Doppelblind-Studie. Klin Padiatr 1997;209(3):100-4.
Fiocchi A, Sala M, Signoroni P, Banderali G, Agostoni C, Riva E. The efficacy and safety of gamma-linolenic acid in the treatment of infantile atopic dermatitis. J Int Med Res 1994;22(1):24-32.
Guivernau M, Meza N, Barja P, Roman O. Clinical and experimental study on the long-term effect of dietary gamma-linolenic acid on plasma lipids, platelet aggregation thromboxane formation, and prostacyclin production. Prostaglandins, Leucotrienes, Essential Fatty Acids. Reviews 1994;51:311-316.
Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG, Veenhuizen R, Muggli R, Raederstorff D. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol 1999;140(4):685-8.
Horrobin DF, Manku MS. Premenstrual syndrome and premenstrual breast pain (Cyclical Mastalgia): Disorders of essential fatty acid (EFA) metabolism. Prostaglandins, Leucotrienes, Essential Fatty Acids. Reviews 1989;37:255-262.
Leson G, Pless P. Hanfsamen und Hanföl. In: Grotenhermen F, Hrsg. Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potential. Göttingen: Hans Huber Verlag, 2001.
Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gamma-linolenic acid. Ann Intern Med 1993;19:867-873.
Melnik BC. Eine Chance zur Pravention atopischer Erkrankungen. Monatsschr Kinderheilkd 1990;138(3):162-6.
Pullman-Mooar S, Laposata M, Lem D, Holman RT, Leventhal LJ, DeMarco D, Zurier RB. Alterations of the cellular fatty acid profile on the production of eicosanoids in human monocytes by gamma-linolenic acid. Arthritis Rheum 1990;33:1526-1533.
Schafer L, Kragballe K. Supplementation with evening primrose oil in atopic dermatitis: effect on fatty acids in neutrophils and epidermis. Lipids 1991;26(7):557-60.
Sellmeyer A, Witzgall H, Lorenz R, Weber PC. N-3 Fettsäuren: Natürliche Antiarrhythmika? Dt. Ärzteblatt 1996;93:2145-2148.

 Laissez une réponse

  • (Se sera pas publier)